FibroGen (United States)

Recent papers from FibroGen (United States)

1. B77-13 Nrf2 Activation With Dimethyl And Monomethyl Fumarate Suppresses Fibrotic Gene Programs In Human IPF Cells And Lung TissueAmerican Journal of Respiratory and Critical Care Medicine · 2026
2. Performance Analysis of a PV Power Plant Installed on the RoofDüzce Üniversitesi Bilim ve Teknoloji Dergisi · 2026
3. LAPIS: A Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Neoadjuvant Pamrevlumab With Chemotherapy for Patients With Locally Advanced Pancreatic CancerJCO oncology advances. · 2026
4. Choline and CCL22 Are Prognostic Blood Biomarkers for Hermansky-Pudlak Syndrome Pulmonary FibrosisAmerican Journal of Respiratory Cell and Molecular Biology · 2025
5. Targeting cannabinoid receptor 1 for antagonism in pro-fibrotic alveolar macrophages mitigates pulmonary fibrosisJCI Insight · 2025
6. Minimum clinically important difference in Quantitative Lung Fibrosis score associated with all-cause mortality in idiopathic pulmonary fibrosis: subanalysis from two phase II trials of pamrevlumabBMJ Open · 2025
7. Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostate CancerJournal of Clinical Oncology · 2025
8. Discovery of Novel, Potent, Orally Bioavailable and Efficacious, Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors for Hematopoietic Stem Cell MobilizationJournal of Medicinal Chemistry · 2025
9. Pamrevlumab did not meet its primary endpoint for ambulatory patients with Duchenne Muscular Dystrophy: the LELANTOS-2 trial2025
10. Pamrevlumab did not meet its primary endpoint for non-ambulatory patients with Duchenne Muscular Dystrophy: the LELANTOS-1 trial2025
11. US Clinical Practice Experience with Eculizumab in Myasthenia Gravis: Acute Clinical Events and Healthcare Resource UtilizationDrugs - Real World Outcomes · 2024
12. Efficacy and Safety of Roxadustat for Anemia in Patients Receiving Chemotherapy for Nonmyeloid Malignancies: A Randomized, Open-Label, Active-Controlled Phase III StudyJournal of Clinical Oncology · 2024
13. Mechanical Stress-induced Connective Tissue Growth Factor Plays a Critical Role in Intestinal Fibrosis in Crohn's-like ColitisAJP Gastrointestinal and Liver Physiology · 2024
14. United States clinical practice experience with eculizumab in myasthenia gravis: symptoms, function, and immunosuppressant therapy useJournal of Neurology · 2024
15. Roxadustat versus placebo for patients with lower‐risk myelodysplastic syndrome: MATTERHORN phase 3, double‐blind, randomized controlled trialAmerican Journal of Hematology · 2024
16. Pamrevlumab for Idiopathic Pulmonary FibrosisJAMA · 2024
17. Updates in Clinical Management of Pancreatic CancerJournal of the National Comprehensive Cancer Network · 2024
18. A phase 3b, multicenter, open‐label, single‐arm study of roxadustat within a US dialysis organization: The DENALI studyHemodialysis International · 2023
19. Functional Pdgfra fibroblast heterogeneity in normal and fibrotic mouse lungJCI Insight · 2023
20. Pamrevlumab, a Fully Human Monoclonal Antibody Targeting Connective Tissue Growth Factor, for Non-Ambulatory Patients with Duchenne Muscular DystrophyJournal of Neuromuscular Diseases · 2023